Lifestyle Asset Management Inc. Trims Stake in United Therapeutics Co. (NASDAQ:UTHR)

Lifestyle Asset Management Inc. reduced its position in United Therapeutics Co. (NASDAQ:UTHR) by 2.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,714 shares of the biotechnology company’s stock after selling 77 shares during the period. United Therapeutics accounts for about 0.7% of Lifestyle Asset Management Inc.’s holdings, making the stock its 25th biggest holding. Lifestyle Asset Management Inc.’s holdings in United Therapeutics were worth $1,310,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Veracity Capital LLC lifted its holdings in shares of United Therapeutics by 134.3% in the 4th quarter. Veracity Capital LLC now owns 2,523 shares of the biotechnology company’s stock valued at $890,000 after purchasing an additional 1,446 shares during the last quarter. Galvin Gaustad & Stein LLC lifted its holdings in shares of United Therapeutics by 6.0% in the 4th quarter. Galvin Gaustad & Stein LLC now owns 26,512 shares of the biotechnology company’s stock valued at $9,354,000 after purchasing an additional 1,505 shares during the last quarter. Inspire Investing LLC increased its position in United Therapeutics by 18.2% in the 4th quarter. Inspire Investing LLC now owns 8,351 shares of the biotechnology company’s stock valued at $2,946,000 after acquiring an additional 1,286 shares during the period. Janney Montgomery Scott LLC increased its position in United Therapeutics by 9.1% in the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock valued at $3,326,000 after acquiring an additional 789 shares during the period. Finally, SG Americas Securities LLC increased its position in United Therapeutics by 117.3% in the 4th quarter. SG Americas Securities LLC now owns 3,244 shares of the biotechnology company’s stock valued at $1,145,000 after acquiring an additional 1,751 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In related news, Director Christopher Causey sold 510 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the sale, the director now owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This represents a 12.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 7,800 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $350.00, for a total value of $2,730,000.00. Following the completion of the sale, the chief financial officer now directly owns 6,978 shares in the company, valued at approximately $2,442,300. The trade was a 52.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 146,848 shares of company stock valued at $55,165,099 in the last quarter. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $371.89 on Friday. The business’s 50 day simple moving average is $365.04 and its 200-day simple moving average is $355.24. The firm has a market capitalization of $16.60 billion, a price-to-earnings ratio of 16.33, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.38 EPS. On average, equities analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several recent research reports. UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. TD Cowen boosted their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. The Goldman Sachs Group boosted their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. HC Wainwright boosted their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH boosted their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $378.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.